¤ OpenAccess: Bronze

This work has “Bronze” OA status. This means it is free to read on the publisher landing page, but without any identifiable license.

<i>EGFR</i>Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Páez,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,Bruce E. Johnson,Matthew Meyerson

Gefitinib

Lung cancer

Epidermal growth factor receptor

2004

Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.

Cite this:

Generate Citation

“<i>EGFR</i>Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy” is a paper by J. Guillermo Páez Pasi A. Jänne Jeffrey C. Lee Sean Tracy Heidi Greulich Stacey Gabriel Paula Herman Frederic J. Kaye Neal I. Lindeman Titus J. Boggon Katsuhiko Naoki Hidefumini Sasaki Yoshitaka Fujii Michael J. Eck William R. Sellers Bruce E. Johnson Matthew Meyerson published in 2004. It has an Open Access status of “bronze”. You can read and download a PDF Full Text of this paper here.